Cantor Fitzgerald Reiterates Overweight on BridgeBio Pharma, Maintains $70 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Josh Schimmer has reiterated an Overweight rating on BridgeBio Pharma (NASDAQ:BBIO) and maintained a $70 price target.
September 16, 2024 | 3:26 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated an Overweight rating on BridgeBio Pharma, maintaining a $70 price target, indicating confidence in the company's potential for growth.
The reiteration of an Overweight rating and a $70 price target by a reputable analyst suggests a positive outlook for BridgeBio Pharma. This can lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100